1-Cyclopropyl-6,8-difluoro-5-(2-hydroxyethylamino)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid | 119354-67-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 1-Cyclopropyl-6,8-difluoro-5-(2-hydroxyethylamino)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
• CAS: 119354-67-5
• 化学式: C₂₀H₂₄F₂N₄O₄
• 分子量: 422.432
• InChiKey: JFVXSFANCNRCBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  96.4
• 氢给体数：
  3
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  1-cyclopropyl-5,6,8-trifluoro-1,4-dihydro-7-(4-methyl-1-piperazinyl)-4-oxo-quinoline-3-carboxylic acid 生成 1-Cyclopropyl-6,8-difluoro-5-(2-hydroxyethylamino)-7-(4-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
  参考文献：
  名称：

  PETERSEN, UWE;GROHE, KLAUS;SCHRIEWER, MICHAEL;SCHENKE, THOMAS;HALLER, ING+

  摘要：

  DOI：

文献信息

• 5-Substituierte Chinolon- und Naphthyridoncarbonsäure-Derivate
  申请人：BAYER AG

  公开号：EP0284935A1

  公开（公告）日：1988-10-05

  Die Erfindung betrifft 5-substituierte Chinolon-und Naphthyridoncarbonsäure-Derivate der Formel (I) in welcher X, Y, R', R2 und R3 die in der Beschreibung angegebene Bedeutung haben. Verfahren zu ihrer Herstellung sowie diese enthaltende antibakterielle Mittel und Futterzusatzstoffe.

  本发明涉及式(I)的5-取代喹诺酮和萘啶酮羧酸衍生物，其中X，Y，R'，R2和R3具有描述中所述的含义。制备它们的方法以及包含它们的抗菌剂和饲料添加剂。
• Pyridonecarboxylic acids as antibacterial agents. Part 14. Synthesis and structure-activity relationships of 5-substituted 6,8-difluoroquinolones, including sparfloxacin, a new quinolone antibacterial agent with improved potency
  作者：Teruyuki Miyamoto、Junichi Matsumoto、Katsumi Chiba、Hiroshi Egawa、Kohichiro Shibamori、Akira Minamida、Yoshiro Nishimura、Hidetsugu Okada、Masahiro Kataoka

  DOI：10.1021/jm00168a018

  日期：1990.6

  A series of 5,7-disubstituted 1-cyclopropyl-6,8-difluoro-4(1H)-oxoquinoline-3-carboxylic acids (10-36) were prepared; the C-5 substituent in these compounds comprised halo, hydroxy, mercapto, and amino groups and the C-7 functional group included variously substituted piperazines. In vitro antibacterial screening results indicated that the amino group was optimal among the C-5 substituents. A combination of the C-5 amino group and the C-7 3,5-dimethylpiperazinyl appendage in this series conferred the best overall antibacterial property with lack of adverse drug interactions. Compound 36k [named sparfloxacin, originally AT-4140, 5-amino-1-cyclopropyl-6,8-difluoro-7-(cis-3,5-dimethyl-1-piperazinyl)- 4(1H)-oxoquinoline-3-carboxylic acid] was superior to ciprofloxacin in both in vitro and in vivo potency and hence was selected as a promising candidate for an improved therapeutic agent.
• PETERSEN, UWE;GROHE, KLAUS;SCHRIEWER, MICHAEL;SCHENKE, THOMAS;HALLER, ING+
  作者：PETERSEN, UWE、GROHE, KLAUS、SCHRIEWER, MICHAEL、SCHENKE, THOMAS、HALLER, ING+

  DOI：——

  日期：——
• MIYAMOTO, TERUYUKI;MATSUMOTO, JUN-ICHI;CHIBA, KATSUMI;EGAWA, HIROSHI;SHIB+, J. MED. CNEM., 33,(1990) N, C. 1645-1656
  作者：MIYAMOTO, TERUYUKI、MATSUMOTO, JUN-ICHI、CHIBA, KATSUMI、EGAWA, HIROSHI、SHIB+

  DOI：——

  日期：——